Johnson & Johnson (JNJ)
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Johnson & Johnson Stock Still Has Room To Run
On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its "outdated" superstar Stelara was more than offset by the strong performance of its oncology franchise. Sales of Erleada, which is becoming the "gold standard" in prostate cancer treatment, reached $908 million, up 17.8% quarter-over-quarter.
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
3 Top Dividend Kings I'm Planning on Buying
Finding dividend stocks that are reliable and have the balance sheet stability and cash flow profile to continue to grow their distributions over the long-term is what many investors are after.
US FDA says J&J's Ethicon issues correction related to surgical stapler
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "most serious".
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street.
